Home › Research › Drug development
Highly specific and selective anti-pS396-tau antibody C10.2 targets seeding-competent tau
Nina Rosenqvist, Ayodeji A Asuni, Christian R Andersson, Søren Christensen, Justus A Daechsel, Jan Egebjerg, Jeppe Falsig, Lone Helboe et al.. Alzheimer's & dementia (New York, N. Y.), 2018-10-14
Topic: Disease mechanisms in lab and animal studies
The antibody C10.2 bound specifically to pS396-tau with an IC50 of 104 pM and detected preferentially hyperphosphorylated tau aggregates from AD brain with an IC50 of 1.2 nM. C10.2 significantly reduced tau seeding of P301L human tau in HEK293 cells, murine cortical neurons, and mice. AD brain extracts depleted with C10.2 were not able to seed tau in vitro and in vivo, demonstrating that C10.2 specifically recognized pathologic seeding-competent tau. Targeting pS396-tau with an antibody like C10.2 may provide therapeutic benefit in AD and other tauopathies.
Key findings
- The antibody C10.2 bound specifically to pS396-tau with an IC50 of 104 pM and detected preferentially hyperphosphorylated tau aggregates from AD brain with an IC50 of 1.2 nM.
- C10.2 significantly reduced tau seeding of P301L human tau in HEK293 cells, murine cortical neurons, and mice.
- AD brain extracts depleted with C10.2 were not able to seed tau in vitro and in vivo, demonstrating that C10.2 specifically recognized pathologic seeding-competent tau.
- Targeting pS396-tau with an antibody like C10.2 may provide therapeutic benefit in AD and other tauopathies.
New to this subject? Start with our plain-English guide: Treatments →
Study details
- Evidence strengthLow
How this study scored 43/100
Published in a leading specialty journal. Scored zero for study design, sample size, effect reported, studied in people and randomised / blinded because the record does not state it. We have no data on journal's citation record, times cited, citations per year, impact for its field and year, cited by studies here, still being cited, senior author's track record, institution's track record, multi-centre collaboration and free to read, so those were left out: it earned 24 of the 56 points we could judge it on, which is 43 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 9 / 10 | Tier 2 — leading specialty journal (Alzheimer's & dementia (New York, N. Y.)) |
| Journal's citation record | — / 4 | No journal record from OpenAlex — left out of this score |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 2 / 5 | 2018 — within 10 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomised / blinded | 0 / 2 | No randomisation or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | — / 7 | No citation count (not found in OpenAlex) — left out of this score |
| Citations per year | — / 5 | No citation count or no year — left out of this score |
| Impact for its field and year | — / 6 | No field-weighted citation impact (OpenAlex has none yet) — left out of this score |
| Cited by studies here | — / 6 | Not yet checked against this library's citation graph — left out of this score |
| Still being cited | — / 4 | No yearly citation counts — left out of this score |
| Senior author's track record | — / 4 | Senior author's record not available — left out of this score |
| Institution's track record | — / 3 | No institution listed in OpenAlex — left out of this score |
| Multi-centre collaboration | — / 3 | Institutions not listed — left out of this score |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 30386817) |
| Free to read | — / 2 | Access not recorded — left out of this score |
| Points | 24 / 56 | Scored on 10 of 20 parts. We have no data for the rest, so they are left out: 24 of the 56 points we could judge it on is 43 out of 100. |
| Total | 43 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Free copy unknown: no free-copy check has an answer for this record yet. That does not mean it is paywalled.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
APA 7th
Rosenqvist, N., Asuni, A. A., Andersson, C. R., Christensen, S., Daechsel, J. A., Egebjerg, J., et al. (2018). Highly specific and selective anti-pS396-tau antibody C10.2 targets seeding-competent tau. Alzheimer's & dementia (New York, N. Y.). https://doi.org/10.1016/j.trci.2018.09.005
Vancouver
Rosenqvist N, Asuni AA, Andersson CR, Christensen S, Daechsel JA, Egebjerg J, et al. Highly specific and selective anti-pS396-tau antibody C10.2 targets seeding-competent tau. Alzheimer's & dementia (New York, N. Y.). 2018. doi:10.1016/j.trci.2018.09.005. PMID: 30386817.
BibTeX
@article{rosenqvist2018-30386817,
author = {Rosenqvist, Nina and Asuni, Ayodeji A and Andersson, Christian R and Christensen, Søren and Daechsel, Justus A and Egebjerg, Jan and Falsig, Jeppe and Helboe, Lone and others},
title = {{Highly specific and selective anti-pS396-tau antibody C10.2 targets seeding-competent tau}},
journal = {Alzheimer's \& dementia (New York, N. Y.)},
year = {2018},
doi = {10.1016/j.trci.2018.09.005},
pmid = {30386817},
url = {https://doi.org/10.1016/j.trci.2018.09.005}
}
Related studies in Drug development
Also tagged “phosphorylation”
387 studies in the library carry the topic tag “phosphorylation”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 387 tagged studies.